RTP Mobile Logo
Current Strategies and Ongoing Research in the Management of Advanced Prostate Cancer
Released April 2016

Proceedings from a CME symposium held at the 2016 Genitourinary Cancers Symposium. Featuring perspectives from Drs Philip Kantoff, William K Oh, Daniel P Petrylak, A Oliver Sartor and Matthew R Smith. (Video Program)

CE Disclosures and Faculty Information

    This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals.

    Cancers of the genitourinary (GU) system affect hundreds of thousands of individuals within the United States each year and account for almost 30% of new cancer diagnoses. Although GU cancers are a diverse array of distinct diseases, tumors of the prostate are among the most prevalent and are therefore the topic of extensive ongoing clinical research. Consequently, the clinical management of this disease is constantly evolving, necessitating rapid and consistent access to learning opportunities for clinicians who provide care for these patients.

    These video proceedings from a CME symposium held during the 2016 Genitourinary Cancers Symposium feature discussions regarding the practice patterns of a cohort of prostate cancer (PC) investigators and related clinical research findings. By providing information on the latest research developments in the context of expert perspectives, this activity will assist medical and radiation oncologists, urologists and other healthcare professionals with the formulation of state-of-the-art clinical management strategies to facilitate optimal care for patients with PC.

    • Appraise recent data on diagnostic and therapeutic advances in PC, and integrate this information, as appropriate, into current clinical care.
    • Explore emerging data on the use of cytotoxic therapy in the setting of hormone-sensitive advanced PC, and consider this information when designing initial treatment plans for appropriate individuals.
    • Recall existing and emerging research information demonstrating the effects of secondary hormonal interventions on quality and quantity of life for patients with castration-resistant PC, and use this information to guide therapeutic decision-making.
    • Consider available research data and expert perspectives on the efficacy and safety of radium-223 dichloride as monotherapy or in combination with other treatment modalities, and use this information to appropriately integrate this novel radiopharmaceutical agent into clinical practice.
    • Effectively apply evidence-based research findings in the determination of best-practice sequencing of available immunotherapeutic, chemotherapeutic and secondary hormonal agents for patients with metastatic PC.
    • Explore the emerging data and active research evaluating novel agents and strategies in the setting of PSA-only recurrent or advanced PC, and discuss the biologic basis for their clinical activity.
    • Counsel appropriately selected patients with recurrent, asymptomatic and symptomatic metastatic PC about the availability of and participation in ongoing clinical trials.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity consists of a video component.

    CME credit is no longer available for this issue

    It is the policy of Research To Practice and Yale Continuing Medical Education to ensure balance, independence, objectivity and scientific rigor in all their educational programs. All faculty, planners and managers participating in this activity are required to disclose any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interest. Research To Practice and Yale Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Daniel P Petrylak, MD (Co-Chair)
    Professor of Medicine
    Director, Prostate and GU Medical Oncology
    Co-Director, Signal Transduction Program
    Yale Cancer Center
    New Haven, Connecticut

    Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Dendreon Pharmaceuticals Inc, Exelixis Inc, Ferring Pharmaceuticals, Johnson & Johnson Pharmaceuticals, Medivation Inc, Pfizer Inc, Sanofi, Takeda Oncology; Contracted Research: Celgene Corporation, Sanofi; Grant Support: Dendreon Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, OncoGenex Pharmaceuticals Inc, Progenics Pharmaceuticals Inc.

    Philip Kantoff, MD
    Chairman of Medicine
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Advisory Committee: Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, BIND Biosciences Inc, Blend Therapeutics, BN ImmunoTherapeutics Inc, Cristal Therapeutics, Endocyte Inc, Genentech BioOncology, GTx Inc, Ipsen, Janssen Biotech Inc, Medivation Inc, Merck, Metamark Genetics Inc, MorphoSys, MTG Biotherapeutics Inc, Omnitura Therapeutics, OncoCellMDx Inc, Pfizer Inc, Sanofi, SOTIO LLC, Takeda Oncology, Tokai Pharmaceuticals Inc; Consulting Agreements: Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Pfizer Inc; Data and Safety Monitoring Board: Genentech BioOncology, Merck, OncoGenex Pharmaceuticals Inc; Stock Ownership: Bellicum Pharmaceuticals Inc, Blend Therapeutics, Metamark Genetics Inc.

    William K Oh, MD
    Chief, Division of Hematology and Medical Oncology
    Professor of Medicine and Urology
    Ezra M Greenspan, MD Professor in Clinical Cancer Therapeutics
    Mount Sinai School of Medicine
    Associate Director of Clinical Research
    The Tisch Cancer Institute
    Mount Sinai Health System
    New York, New York

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, DAVA Oncology, Inovio Pharmaceuticals Inc, Janssen Biotech Inc, Sanofi, Seattle Genetics, Teva Oncology.

    A Oliver Sartor, MD
    Medical Director
    Tulane Cancer Center
    Laborde Professor of Cancer Research
    Professor of Medicine and Urology
    Tulane Medical School
    New Orleans, Louisiana

    Consulting Agreements: Astellas Pharma Global Development Inc, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Medivation Inc, Sanofi; Contracted Research: Bayer HealthCare Pharmaceuticals, Progenics Pharmaceuticals Inc, Sanofi.

    Matthew R Smith, MD, PhD
    Claire and John Bertucci Endowed Chair in Genitourinary Cancers
    Professor of Medicine
    Harvard Medical School
    Director, Genitourinary Malignancies Program
    Massachusetts General Hospital Cancer Center
    Boston, Massachusetts

    Advisory Committee: Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals; Consulting Agreements: Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals; Contracted Research: Bayer HealthCare Pharmaceuticals.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice and Yale Continuing Medical Education do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider, publisher or grantors.

    This activity is supported by educational grants from Astellas Pharma Global Development Inc/Medivation Inc, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Sanofi and Tokai Pharmaceuticals Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: April 2016
    Expiration date: April 2017

Acknowledge and close

View video: